Evaluation of diabetic patients after three month use of continuous subcutaneous insulin infusion, dispensed by a protocolled form at outpatient reference clinic of Taguatinga Regional Hospital.
OBJECTIVE
To evaluate the data of continuous subcutaneous insulin infusion protocol (CSII) for diabetics waived by the Health State Secretariat of Distrito Federal (HSSDF) and therapeutic responses three months after the transfer of multiple daily injections regimen for CSII.


METHODS
Eighty patients (49 female) took part in this experimental study, mean age and disease duration were 27.9 years and 13 years, respectively; 96% patients had type 1 diabetes mellitus.


RESULTS
The entire sample (ECO) and 3 subgroups (group 1 - A1c decrease, group 2 - A1c stable, and group 3 - A1c increase), stratified according to a ≥ 0.5% change in A1c, were analyzed. Group 1 involved 64% of the patients. The ECO showed a significant A1c decrease: MDI 8.1 ± 1.4% vs. CSII 7.3 ± 0.9%, p < 0.0001 (0.8% difference pro CSII therapy). Group 1 demonstrated an A1c decrease from 8.7% to 7.3% (1.4% difference). Group 2 mean A1c was 7.1%. Rate of hypoglycemia (< 50 mg/dL) decreased 61% in the ECO and 79% in Group 2.


CONCLUSIONS
This study reinforces the safety and efficacy of CSII with a robust A1c reduction and hypoglycemia. The pioneer care HSSDF ambulatory attests to be achievable the free dispensing by Unified Health System (UHS) following a protocol, and this approach results in less wastage to the patient and represents a rational policy of therapy with CSII for UHS.
Research Centre, Taguatinga Regional Hospital, Brasília, DF, Brazil.
Leonardo Garcia
LG
Miranda
Research Centre, Taguatinga Regional Hospital, Brasília, DF, Brazil.
Hermelinda Cordeiro
HC
Pedrosa
Research Centre, Taguatinga Regional Hospital, Brasília, DF, Brazil.
Roberta Kelly Menezes Maciel
RK
Falleiros
Research Centre, Taguatinga Regional Hospital, Brasília, DF, Brazil.
Renata de Moraes
Rde M
Oliveira
Research Centre, Taguatinga Regional Hospital, Brasília, DF, Brazil.
Monica
M
Tolentino
Section of Endocrinology, University Hospital of Brasília, Brasília, DF, Brazil.
Luiz Augusto
LA
Casulari
D000293:Adolescent; D000328:Adult; D000554:Ambulatory Care Facilities; D001938:Brazil; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006779:Hospitals, Public; D006801:Humans; D007003:Hypoglycemia / Q000097:blood; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D055104:Infusions, Subcutaneous / Q000379:methods; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D008297:Male; D010045:Outpatients; D011446:Prospective Studies; D055815:Young Adult
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin